Composition of Certain Financial Statement Captions (Details 2) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014
Goodwill [Roll Forward]
Beginning balance	$ 226,373	[1]
Acquisitions	0
Foreign exchange, other	(1,604)
Ending balance	224,769	[1]
Pharmaceutical | CURNA
Goodwill [Roll Forward]
Beginning balance	4,827
Acquisitions	0
Foreign exchange, other	0
Ending balance	4,827
Pharmaceutical | OPKO Mexico
Goodwill [Roll Forward]
Beginning balance	113
Acquisitions	0
Foreign exchange, other	(3)
Ending balance	110
Pharmaceutical | OPKO Chile
Goodwill [Roll Forward]
Beginning balance	6,102
Acquisitions	0
Foreign exchange, other	(784)
Ending balance	5,318
Pharmaceutical | OPKO Health Europe
Goodwill [Roll Forward]
Beginning balance	9,075
Acquisitions	0
Foreign exchange, other	(712)
Ending balance	8,363
Pharmaceutical | FineTech
Goodwill [Roll Forward]
Beginning balance	11,698
Acquisitions	0
Foreign exchange, other	0
Ending balance	11,698
Pharmaceutical | SciVac
Goodwill [Roll Forward]
Beginning balance	1,740
Acquisitions	0
Foreign exchange, other	(105)
Ending balance	1,635
Pharmaceutical | OPKO Renal
Goodwill [Roll Forward]
Beginning balance	2,069
Acquisitions	0
Foreign exchange, other	0
Ending balance	2,069
Pharmaceutical | OPKO Biologics
Goodwill [Roll Forward]
Beginning balance	139,784
Acquisitions	0
Foreign exchange, other	0
Ending balance	139,784
Diagnostics | OPKO Diagnostics
Goodwill [Roll Forward]
Beginning balance	17,977
Acquisitions	0
Foreign exchange, other	0
Ending balance	17,977
Diagnostics | OPKO Lab
Goodwill [Roll Forward]
Beginning balance	32,988
Acquisitions	0
Foreign exchange, other	0
Ending balance	$ 32,988

[1] As of September 30, 2014 and December 31, 2013, total assets include $7.4 million and $6.7 million, respectively, and total liabilities include $13.1 million and $10.4 million, respectively, related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities have no recourse against us. Refer to Note 5.